Pure Global AI
NCT06233292Recruiting

A Study of ZG005 in Patients With Advanced Solid Tumors

A Phase 1/2 Dose Escalation, Tolerability, Safety and Pharmacokinetics Study of ZG005 in Patients With Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co.,LtdPhase 1/2ClinicalTrials.govbiological
Verified
Study focus
Disease/Condition
Solid Tumors
Drug/Device/Intervention
ZG005 Powder for Injection
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Location
Changchun, China
Timeline & enrollment
Phase
Phase 1/2
Start date
Jun 17, 2022
End date
Jan 01, 2026
Enrollment
484 participants
Primary outcome

Dose Limiting Toxicities (DLT),Adverse Event (AE),Objective Response Rate,Maximum tolerated dose (MTD)

Summary

This is a multi-center, open-label, Phase 1/2 study of ZG005 for the treatment of subjects
 with advanced solid tumors, and consists of three stages: dose escalation and confirmation of
 MTD/recommended dose.

ICD-10 classifications
Malignant neoplasm: Connective and soft tissue, unspecifiedMalignant neoplasm of other connective and soft tissueCarcinoma in situ, unspecifiedMalignant neoplasmsMalignant neoplasm: Parametrium
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06233292
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06233292 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd and is currently Recruiting. The study focuses on Solid Tumors. Target enrollment is 484 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.